Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01415505 · ClinicalTrials.gov registry record · Phase 3
Combination of Nebivolol and Valsartan Given as Free Tablets for Stage 1 or Stage 2 Hypertension
A Phase 3 study, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 3
- Development phase
- 812
- Enrollment target
NCT01415505 is a Phase 3 study that has completed, run by Forest Laboratories. The registered enrollment target is 812 participants.
The verdict
NCT01415505, a Phase 3 study, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 812 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of nebivolol and valsartan given as a free tablet combination in patient with stage 1 or stage 2 essential hypertension.
Interventions
- DRUG Nebivolol, Valsartan and Hydrochlorothiazide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 812 participants |
| Start Date | 2011-08 |
| Est. Completion | 2013-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01415505
The ClinicalTrials.gov registry entry for NCT01415505 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 812 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nebivolol, Valsartan and Hydrochlorothiazide is the first listed.
NCT01415505 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01415505 about?
NCT01415505 is a clinical study titled "Combination of Nebivolol and Valsartan Given as Free Tablets for Stage 1 or Stage 2 Hypertension". The purpose of this study is to evaluate the safety and tolerability of nebivolol and valsartan given as a free tablet combination in patient with stage 1 or stage 2 essential hypertension.
What is the current status of trial NCT01415505?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 812 participants. The study started on 2011-08. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01415505?
The interventions under investigation include: Nebivolol, Valsartan and Hydrochlorothiazide (DRUG).
Who is sponsoring clinical trial NCT01415505?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.